Novo Nordisk A/S (NVO)
47.78
+0.01
(+0.02%)
USD |
NYSE |
Dec 18, 10:59
Novo Nordisk Research and Development Expense (TTM): 7.615B for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Evaxion AS | 9.769M |
| Ascendis Pharma A/S | 326.69M |
| Regeneron Pharmaceuticals, Inc. | 5.097B |
| Omeros Corp. | 84.14M |
| Viking Therapeutics, Inc. | 222.48M |